TY - JOUR
T1 - The role of statins in cancer therapy
AU - Hindler, Katja
AU - Cleeland, Charles S.
AU - Rivera, Edgardo
AU - Collard, Charles D.
PY - 2006/3
Y1 - 2006/3
N2 - Administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, to ambulatory patients is associated with a lower incidence of long-term adverse cardiovascular events, including death, myocardial infarction, stroke, atrial fibrillation, and renal dysfunction. However, increasing clinical evidence suggests that statins, independent of their effects on serum cholesterol levels, may also play a potential role in the prevention and treatment of cancer. Specifically, statins have been shown to exert several beneficial antineoplastic properties, including decreased tumor growth, angiogenesis, and metastasis. The feasibility and efficacy of statins for the prevention and treatment of cancer is reviewed.
AB - Administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, to ambulatory patients is associated with a lower incidence of long-term adverse cardiovascular events, including death, myocardial infarction, stroke, atrial fibrillation, and renal dysfunction. However, increasing clinical evidence suggests that statins, independent of their effects on serum cholesterol levels, may also play a potential role in the prevention and treatment of cancer. Specifically, statins have been shown to exert several beneficial antineoplastic properties, including decreased tumor growth, angiogenesis, and metastasis. The feasibility and efficacy of statins for the prevention and treatment of cancer is reviewed.
KW - Chemotherapy
KW - HMG-CoA reductase inhibitor
KW - Inflammation
KW - Prevention
KW - Tumor
UR - http://www.scopus.com/inward/record.url?scp=33645047418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645047418&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.11-3-306
DO - 10.1634/theoncologist.11-3-306
M3 - Review article
C2 - 16549815
AN - SCOPUS:33645047418
SN - 1083-7159
VL - 11
SP - 306
EP - 315
JO - Oncologist
JF - Oncologist
IS - 3
ER -